Celator Pharmaceuticals

Our Mission: Improving and Extending the Lives of Patients with Cancer

General CPX-351 CPX-1 CPX-571 Nanoparticle Prodrug Delivery Other

Publications: CPX-1

Manuscripts

	Safety, Pharmacokinetics, and Efficacy of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in Patients with Advanced Solid Tumors \| Batist et al, Clin Cancer Res 2009 Jan 15; 15(2): 692-700

	Intra- and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes \| Dicko et al, Pharm Res 2008; 25(7): 1702-1713

	Increased Preclinical Efficacy of Irinotecan and Floxuridine Coencapsulated Inside Liposomes Is Associated with Tumor Delivery of Synergistic Drug Ratios \| Harasym et al, Oncol Res 2007; 16(8): 361-374

	Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo \| Tardi et al, Biochim Biophys Acta 2007 Mar; 1768(3): 678-687

Abstracts
Click abstract title to view poster

	CPX-1, a liposome formulation containing a synergistic 1:1 molar ratio of irinotecan and floxuridine, exhibits increased efficacy in combination with either bevacizumab (BEV) or cetuximab (CET) in human colorectal cancer (CRC) solid tumor xenograft models \| Tardi et al, American Association for Cancer Research (AACR) Annual Meeting 2009, Abstract #4578

	Preclinical and Phase I Clinical Pharmacokinetics of CPX-1 (Irinotecan HCl:Floxuridine) Lipsome Injection \| Swenson et al, 10th World Congress on Gastrointestinal Cancer (WCGIC) 2008

	Phase 2 Study of CPX-1 Liposome Injection: UGT1A1 and Prediction of Severe Toxicities \| Batist et al, 10th World Congress on Gastrointestinal Cancer (WCGIC) 2008, Abstract #493

	A multicenter, phase 2 study of CPX-1 Liposome Injection in patients with advanced colorectal cancer based on ratiometric dosing \| Batist et al, American Society of Clinical Oncology (ASCO) Annual Meeting 2008, Abstract #4108

	Ratiometric Dosing of Irinotecan and Floxuridine in a Phase I Trial: A New Approach for Enhancing the Activity of Combination Chemotherapy \| Batist et al, American Society of Clinical Oncology (ASCO) Annual Meeting 2007, Abstract #2549

	Phase I Study of CPX-1, a fixed ratio formulation of irinotecan and floxuridine, in patients with advanced solid tumors \| Batist et al, American Society of Clinical Oncology (ASCO) Annual Meeting 2006, Abstract #2014

	A Pharmaceutical Approach to Achieve Synergy In Vivo: A Fixed Ratio Formulation of Irinotecan and Floxuridine for Treatment of Colorectal Cancer \| Mayer et al, American Association for Cancer Research (AACR) Annual Meeting 2004, Abstract #550

	The Therapeutic Activity of Fixed Ratio Formulations of Irinotecan and Floxuridine are Ratio Dependent: Therapeutic Assessment in the Capan-1 Human Pancreatic tumour Xenograft Model \| Mayer et al, American Association for Cancer Research (AACR) Annual Meeting 2004, Abstract #549

CPX-1 is a liposomal formulation of Irinotecan HCl:Floxuridine in a synergistic 1:1 molar ratio.

© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.